391 related articles for article (PubMed ID: 29992180)
1. Bisphosphonate conjugation for bone specific drug targeting.
Farrell KB; Karpeisky A; Thamm DH; Zinnen S
Bone Rep; 2018 Dec; 9():47-60. PubMed ID: 29992180
[TBL] [Abstract][Full Text] [Related]
2. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.
Hirabayashi H; Fujisaki J
Clin Pharmacokinet; 2003; 42(15):1319-30. PubMed ID: 14674786
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery to bone and mineral deposits using bisphosphonate ligands.
Cole LE; Vargo-Gogola T; Roeder RK
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):12-27. PubMed ID: 26482186
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin.
Bhandari KH; Newa M; Uludag H; Doschak MR
Int J Pharm; 2010 Jul; 394(1-2):26-34. PubMed ID: 20412845
[TBL] [Abstract][Full Text] [Related]
6. Targeting therapeutics to bone by conjugation with bisphosphonates.
Young RN; Grynpas MD
Curr Opin Pharmacol; 2018 Jun; 40():87-94. PubMed ID: 29626715
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
[TBL] [Abstract][Full Text] [Related]
9. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Shakespeare WC; Metcalf CA; Wang Y; Sundaramoorthi R; Keenan T; Weigele M; Bohacek RS; Dalgarno DC; Sawyer TK
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):729-41. PubMed ID: 14579523
[TBL] [Abstract][Full Text] [Related]
10. Bone Targeting Nanoparticles for the Treatment of Osteoporosis.
Wen C; Xu X; Zhang Y; Xia J; Liang Y; Xu L
Int J Nanomedicine; 2024; 19():1363-1383. PubMed ID: 38371454
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer.
Nadar RA; Margiotta N; Iafisco M; van den Beucken JJJP; Boerman OC; Leeuwenburgh SCG
Adv Healthc Mater; 2017 Apr; 6(8):. PubMed ID: 28207199
[TBL] [Abstract][Full Text] [Related]
12. Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer.
El-Mabhouh A; Angelov C; McEwan A; Jia G; Mercer J
Cancer Biother Radiopharm; 2004 Oct; 19(5):627-40. PubMed ID: 15650456
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
14. Normal osteoconduction and repair in and around submerged highly bisphosphonate-complexed hydroxyapatite implants in rat tibiae.
Denissen H; Martinetti R; van Lingen A; van den Hooff A
J Periodontol; 2000 Feb; 71(2):272-8. PubMed ID: 10711618
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering.
Ossipov DA
Expert Opin Drug Deliv; 2015; 12(9):1443-58. PubMed ID: 25739860
[TBL] [Abstract][Full Text] [Related]
16. The role of bisphosphonates in breast and prostate cancers.
Brown JE; Neville-Webbe H; Coleman RE
Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
[TBL] [Abstract][Full Text] [Related]
17. Binding kinetics of a fluorescently labeled bisphosphonate as a tool for dynamic monitoring of bone mineral deposition in vivo.
Tower RJ; Campbell GM; Müller M; Will O; Glüer CC; Tiwari S
J Bone Miner Res; 2014 Sep; 29(9):1993-2003. PubMed ID: 24644087
[TBL] [Abstract][Full Text] [Related]
18. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
19. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
Reitsma PH; Teitelbaum SL; Bijvoet OL; Kahn AJ
J Clin Invest; 1982 Nov; 70(5):927-33. PubMed ID: 7130396
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
